The CBFA2T3::GLIS2 fusion is an exclusively pediatric AML genomic abnormality, occurring in children under 3 years old, and it is associated with a very poor prognosis, with an overall survival rate of 14% (8). This evidence concerns the gene GLIS2 and acute myeloid leukemia.